Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Enrolling by invitation Not applicable

Effect of Carbon Dioxide Pressure on Optic Nerve Sheath Diameter in Laparoscopic Transperitoneal Nephrectomy

NCT07262125 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2024-12-01
Last updated
2025-12-03

Condition(s) studied

Optic Nerve Sheath DiameterLaparoscopic Nephrectomy

Investigational drug(s) / intervention(s)

Optic Nerve Sheath Diameter Measurement

Optic Nerve Sheath Diameter Measurement: Optic Nerve Sheath Diameter Measurement, Oxygen saturation and End Tidal CO2 measurements when Pre-operational Supine position, after intubation, Lateral decubitus position, after Pneumoperitoneum, CO2 pressure level at 14-16-18-20 and Post-operational supine position

Study summary

Nephrectomy is a surgical procedure performed for various indications, and with the development and increasing availability of advanced diagnostic techniques, its incidence has been rising. Today, in appropriate cases, laparoscopic surgery is recommended due to its minimally invasive nature and its surgical success rates being comparable to those of open surgery. In laparoscopic surgery, to achieve optimal visualization, a 45° lateral decubitus position is applied, followed by the creation of a pneumoperitoneum using carbon dioxide gas. While the cardiopulmonary effects of this procedure have been shown to be minimal, studies on its intracranial effects are limited. Cerebral perfusion pressure is defined as the difference between mean arterial pressure and either central venous pressure or intracranial pressure, whichever is higher. Intracranial pressure can be assessed non-invasively using ultrasonographic measurement of the Optic Nerve Sheath Diameter (ONSD). The retrobulbar segment of the optic nerve is surrounded by a distensible subarachnoid space, which expands in response to increased intracranial pressure. The effect of increased intra-abdominal pressure during laparoscopic surgery on intracranial pressure, and its impact on ONSD, will be evaluated non-invasively.

In patients scheduled for laparoscopic kidney surgery, the Optic Nerve Sheath Diameter will be measured transorbitally using ultrasonography by the investigator at various stages of the surgery (before anesthesia, after anesthesia, in the lateral decubitus position, during pneumoperitoneum, and at routine intraoperative pressure levels). Additionally, standard monitoring parameters such as pulse rate, blood pressure, oxygen saturation, and End-Tidal CO₂ will be recorded. The Optic Nerve Sheath Diameter, which serves as an indicator of increased intracranial pressure, will be compared with variables such as surgical positioning, BMI, ASA score, and other relevant factors.

Eligibility

Sex
ALL
Min age
31 Years
Max age
69 Years
Healthy volunteers
No
Inclusion Criteria: * Male and female patients aged 31-69 years. * Diagnosis of renal cancer (ICD Code C64). * Planned laparoscopic radical or partial nephrectomy based on current guidelines and patient consent in the Urology Council. Exclusion Criteria: * Presence of any condition that prevents transorbital measurement of the optic nerve sheath (e.g., orbital trauma, severe periorbital edema, or ocular abnormalities affecting optic nerve imaging) * Presence of a medical condition that precludes positioning the patient in a 45-degree lateral decubitus position (e.g., severe scoliosis, respiratory compromise, or spinal instability) * Known or suspected intracranial pathology that may independently elevate intracranial pressure (e.g., intracranial tumors, hydrocephalus, recent traumatic brain injury)

Primary outcome measure(s)

  • Change in optic nerve sheath diameter (ONSD) with increasing intraabdominal CO₂ pressure — Preop Supine before intubation → During surgery (baseline supine → lateral decubitus positioning → pneumoperitoneum → each pressure level: 14, 16, 18, 20 mmHg → Postop Supine 5 minutes after extubation of the patient
    Change in optic nerve sheath diameter (ONSD) with increasing intraabdominal CO₂ pressure

Trial sites (1)

FacilityCityRegionStatus
Fatih Sultan Mehmet Research and Training Hospital Istanbul Ataşehir
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07262125 on ClinicalTrials.gov ↗ ← All trials in Turkey